A top manufacturer of drug testing technology has announced a new screening panel that no longer detects marijuana and instead prioritizes fentanyl and other controlled substances in response to the “relentless change and the pressing need to adapt” as more states legalize cannabis.
Psychemedics said its updated Advanced 5-Panel Drug Screen “will transform the way organizations safeguard their workplaces, shifting the spotlight from marijuana to the paramount threat of fentanyl.”
The screening panel, which the company said has been approved by the Food and Drug Administration, is also being touted for increased accuracy in the detection of cocaine, opioids, PCP and amphetamines.
“As we grapple with an ongoing labor shortage and with marijuana’s legal landscape evolving in 49 states, it’s clear that the time for a change has come,” Psychemedics, which was founded in 1987 and pioneered the use of hair testing, said in a press release on Friday. “Traditional 5-panel drug tests, rooted in a four-decade-old paradigm, have failed to evolve in today’s drug market and are unable to detect the rising drug, fentanyl.”
Brian Hullinger, president and CEO at Psychemedics said that “few challenges in the workplace have undergone as dramatic a transformation as the shifting dynamics between marijuana
Read full article on Marijuana Moment
